301015 Qingdao Baheal Medical INC.
- 32.98
- -0.98-2.89%
Qingdao Baheal Medical INC. News
Fewer Investors Than Expected Jumping On Qingdao Baheal Medical INC. (SZSE:301015)
With a price-to-earnings (or "P/E") ratio of 24.1x Qingdao Baheal Medical INC. (SZSE:301015) may be sending bullish signals at the moment, given that almost half of all companies in China have P/E rat
Baiyang Pharmaceutical (301015.SZ): Plans to jointly invest in partnerships with professional investment institutions
Gelonghui, April 23 | Baiyang Pharmaceutical (301015.SZ) announced that the company collaborates with AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC Capital Operation Co., Ltd., Shandong New Kinetic Energy Fund Management Co., Ltd., Qingdao Innovation Investment Co., Ltd., Qingdao Hi-Tech Industry Development Parent Fund Partnership (Limited Partnership), Wuxi AstraZeneca CICC Venture Capital Partnership (Limited Partnership), Jinan Hi-Tech Finance Investment Co., Ltd., Yinfeng Finance (Beijing) Investment Management Co., Ltd., and Tianjin Jiashan Industrial Development Investment Co., Ltd. Invested in the establishment of AstraZeneca CICC
Baiyang Pharmaceutical (301015.SZ) plans to invest 50 million yuan in AstraZeneca CICC Qingdao Healthcare Venture Capital Fund to invest in the healthcare sector
Baiyang Pharmaceutical (301015.SZ) announced that the company, AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC...
Baiyang Pharmaceutical (301015.SZ): 2023 net profit of 656 million yuan, plans to distribute 10 to 7.62 yuan
Gelonghui, April 22丨Baiyang Pharmaceutical (301015.SZ) announced its 2023 annual report. Operating income for the reporting period was 7.564 billion yuan, up 0.72% year on year; net profit attributable to shareholders of listed companies was 656 million yuan, up 29.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 635 million yuan, up 25.14% year on year; basic income per share was 1.25 yuan; it plans to pay a cash dividend of 7.62 yuan (tax included) for every 10 shares to all shareholders.
Qingdao Baheal Medical (SZSE:301015) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.
The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities
Guojin Securities: Innovative drugs are an important field for the implementation of scientific and technological progress. Overall, performance will rise simultaneously with market performance
Guojin Securities released a research report saying that global innovative drugs are an important field for realizing scientific and technological progress, and China's innovative drug industry chain is on the rise. With the full restoration of in-hospital diagnosis and treatment, the introduction of national incentives and support policies for innovative drugs one after another, and the pace of internationalization of Chinese pharmaceutical companies, the industry as a whole will usher in simultaneous improvements in performance and market performance. It is recommended to invest in two types of targets: 1) choose a racetrack, preferring domestic targets mapped by metabolic, neurological, and self-immune indications and cutting-edge innovators in overseas breakthroughs; 2) select leaders, which are optimistic about bottom-up and internationalization breakthroughs. Recommended attention: Cinda Biotech (01801), Kangfang Biology
Qingdao Baheal Medical INC. (SZSE:301015) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
It is hard to get excited after looking at Qingdao Baheal Medical's (SZSE:301015) recent performance, when its stock has declined 17% over the past three months. But if you pay close attention, you
Shareholders Are Optimistic That Qingdao Baheal Medical (SZSE:301015) Will Multiply In Value
What are the early trends we should look for to identify a stock that could multiply in value over the long term? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increas
Baiyang Pharmaceutical (301015.SZ): The Diqiao series in operation is still growing. The Diqiao series has various product standards such as adult calcium, maternal and child calcium, and children's calcium
Gelonghui, January 19 | Baiyang Pharmaceutical (301015.SZ) said on the investor interactive platform that the Diqiao series operated by the company is still growing. The Diqiao series has multiple product regulations such as adult calcium, maternal and child calcium, and children's calcium. At the same time, the company will launch calcium preparations for middle-aged and elderly people in due course according to the business plan; currently, the company has formed a multi-brand matrix with four major categories of OTC, DaHealth, OTX and other prescription drugs, and high-end medical devices.% Reduced to the first three quarters of 2023
Baiyang Pharmaceutical (301015.SZ) subsidiary plans to sell 100% of Beijing Baiyang Zhixin's shares to Baiyang Group to reduce business risk
Baiyang Pharmaceutical (301015.SZ) announced that Beijing Baiyang Zhihe Medical Achievement Transformation Service Co., Ltd., a wholly-owned subsidiary of the company...
Baiyang Pharmaceutical (301015.SZ) plans to spend 49.5 million yuan on joint investment funds with professional investment institutions
Baiyang Pharmaceutical (301015.SZ) issued an announcement to achieve the strategic layout of the industry, seize opportunities for strategic cooperation, and fully...
Is Qingdao Baheal Medical INC.'s (SZSE:301015) Latest Stock Performance A Reflection Of Its Financial Health?
Qingdao Baheal Medical's (SZSE:301015) stock is up by a considerable 75% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case i
Baiyang Pharmaceutical (301015.SZ) and its holding subsidiary Baiyang Guosheng signed commercial cooperation strategic agreements with Rideo and Midis respectively
Baiyang Pharmaceutical (301015.SZ) announced that the company signed a contract with Guangdong Redio Technology Co., Ltd. (“Redio”)...
Baiyang Pharmaceutical (301015.SZ): Controlling shareholders have transferred a total of 1.6 million “Baiyang Convertible Bonds”
Gelonghui November 14丨Baiyang Pharmaceutical (301015.SZ) announced that the company recently received a notice from the controlling shareholder Baiyang Pharmaceutical Group Co., Ltd. and learned that it transferred 1.6 million “Baiyang Convertible Bonds” held by it through bulk transactions between November 10, 2023 and November 14, 2023, accounting for 18.60% of the total amount of bonds issued.
The controlling shareholder of Baiyang Pharmaceutical (301015.SZ) reduced its holdings of convertible bonds by 1.6 million
Baiyang Pharmaceutical (301015.SZ) announced that Baiyang Pharmaceutical Group Co., Ltd., the controlling shareholder of the company, announced on 2023/1...
Baiyang Pharmaceutical (301015.SZ): The fully magnetic levitation artificial heart currently in operation is still in the commercial promotion stage, and the impact on the company's performance is small
Gelonghui November 8 | Baiyang Pharmaceutical (301015.SZ) held an investor relations event on November 8, 2023, on “How is the performance of the artificial heart operated by the company?” The company replied that currently the fully magnetic levitation artificial heart operated by the company is still in the commercial promotion stage, and the impact on the company's performance is minimal. Please check the company's regular reports for details on the company's performance.
Baiyang Pharmaceutical (301015.SZ): Currently operating Isnona, Keonis, Hercules, and the restorative beauty of the Xi'an Giants
Gelonghui November 8 | Baiyang Pharmaceutical (301015.SZ) held an investor relations event on November 8, 2023, on “Has the company made any new progress in functional cosmetics?” The company replied that in terms of effective skincare products, the company currently operates Isnona, Keonis, Xynol, and the Xi'an giant's Restorative Beauty. In the future, the company will actively seek cooperation with high-quality, functional skincare companies.
Baiyang Pharmaceutical (301015.SZ): Controlling shareholders reduced their holdings of “Baiyang Convertible Bonds” by a total of 1 million copies
Gelonghui November 8 | Baiyang Pharmaceutical (301015.SZ) announced that the company recently received a notice from Baiyang Pharmaceutical Group Co., Ltd., the controlling shareholder of the company, and learned that it reduced its holdings of “Baiyang Convertible Bonds” by 1 million through bulk transactions on November 8, 2023, accounting for 11.63% of the total number of bonds issued.
Baiyang Pharmaceutical (301015.SZ): Controlling shareholders have reduced their holdings of “Baiyang Convertible Bonds” by a total of 2 million copies
Gelonghui November 3 | Baiyang Pharmaceutical (301015.SZ) announced that the company recently received a notice from Baiyang Pharmaceutical Group Co., Ltd., the controlling shareholder of the company, and learned that during the period from October 30, 2023 to November 3, 2023, it reduced its holdings of 2 million “Baiyang Convertible Bonds” through bulk transactions, accounting for 23.26% of the total amount of bonds issued.
Analysis
Price Target
No Data
